Spyre Therapeutics Inc (SYRE)

Apr 02, 2025

Spyre Therapeutics (NASDAQ:SYRE) Hits New 12-Month LowShould You Sell? - MarketBeat

Apr 02, 2025

Apr 02, 2025

Teacher Retirement System of Texas Takes Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Apr 02, 2025

Mar 30, 2025

Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up – What’s Next? - Defense World

Mar 30, 2025

Mar 29, 2025

Swiss National Bank Buys 19,000 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Mar 29, 2025

Mar 27, 2025

Spyre Therapeutics Starts Dosing in Phase 1 Trial for IL-23 Antibody SPY003 - Marketscreener.com

Mar 27, 2025

Mar 27, 2025

Game-Changing IL-23 Antibody Enters Clinical Trials: Quarterly Dosing Could Transform Treatment - Stock Titan

Mar 27, 2025

Mar 26, 2025

Head to Head Contrast: Spyre Therapeutics (NASDAQ:SYRE) & Aptorum Group (NASDAQ:APM) - Defense World

Mar 26, 2025

Mar 23, 2025

Charles Schwab Investment Management Inc. Has $8.84 Million Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Mar 23, 2025

Mar 22, 2025

Bank of New York Mellon Corp Decreases Stock Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Mar 22, 2025

Mar 20, 2025

Will Spyre Therapeutics Redefine IBD Treatment With Superior Efficacy And Convenience? - RTTNews

Mar 20, 2025

Mar 19, 2025

Spyre Therapeutics (NASDAQ:SYRE) Coverage Initiated by Analysts at Wolfe Research - Defense World

Mar 19, 2025

Mar 18, 2025

Wolfe Research Initiates Spyre Therapeutics at Outperform With $27 Price Target -March 18, 2025 at 07:17 am EDT - Marketscreener.com

Mar 18, 2025

Mar 16, 2025

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by Arizona State Retirement System - Defense World

Mar 16, 2025

Mar 15, 2025

Victory Capital Management Inc. Takes Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Mar 15, 2025

Mar 14, 2025

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of “Buy” by Brokerages - Defense World

Mar 14, 2025

Mar 08, 2025

Spyre Therapeutics Announces Grants of Inducement Awards - cnhinews.com

Mar 08, 2025

Mar 07, 2025

Spyre Therapeutics Inc (SYRE) Announces Stock Option Grants to Non-Executive Employees - GuruFocus.com

Mar 07, 2025

Mar 07, 2025

132,200 New Stock Options: Inside Spyre Therapeutics' Latest Employee Compensation Package - StockTitan

Mar 07, 2025

Mar 06, 2025

Rhumbline Advisers Boosts Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - Defense World

Mar 06, 2025

Mar 04, 2025

Spyre Therapeutics Faces Compliance Hurdles After Transition from Smaller Reporting Company Status - MSN

Mar 04, 2025

Mar 04, 2025

Spyre Therapeutics Inc (SYRE) deserves closer scrutiny - US Post News

Mar 04, 2025

Mar 04, 2025

Spyre Therapeutics: Targeting The Future Of IBD Treatment - Seeking Alpha

Mar 04, 2025

Mar 02, 2025

Spyre Therapeutics (NASDAQ:SYRE) Trading 6.6% Higher After Strong Earnings - Defense World

Mar 02, 2025

Feb 28, 2025

Spyre Therapeutics (NASDAQ:SYRE) Posts Earnings Results, Beats Expectations By $0.08 EPS - MarketBeat

Feb 28, 2025

Feb 28, 2025

Buy Rating for Spyre Therapeutics Driven by Promising Drug Development and Strong Financial Position - TipRanks

Feb 28, 2025

Feb 28, 2025

Spyre Therapeutics: Q4 Earnings Snapshot - The Pioneer

Feb 28, 2025

Feb 28, 2025

Decoding Spyre Therapeutics Inc (SYRE): A Strategic SWOT Insight - GuruFocus.com

Feb 28, 2025

Feb 27, 2025

Spyre Therapeutics Reports Strong Progress and Financial Stability - TipRanks

Feb 27, 2025

Feb 27, 2025

Spyre Therapeutics reports Q4 EPS (81c), consensus (94c) - TipRanks

Feb 27, 2025

Feb 27, 2025

Spyre Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 27, 2025

Feb 27, 2025

Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - PR Newswire

Feb 27, 2025

Feb 27, 2025

Spyre Therapeutics (SYRE) Projected to Post Earnings on Thursday - Defense World

Feb 27, 2025

Feb 26, 2025

Recent Insider Activity Could Benefit Spyre Therapeutics Inc (SYRE) - Knox Daily

Feb 26, 2025

Feb 26, 2025

SYRE Stock Touches 52-Week Low at $20.24 Amid Market Challenges - Investing.com Australia

Feb 26, 2025

Feb 25, 2025

Spyre Therapeutics (NASDAQ:SYRE) Hits New 1-Year LowTime to Sell? - MarketBeat

Feb 25, 2025

Feb 25, 2025

Spyre Therapeutics to Participate in Upcoming March Investor Conferences - PR Newswire

Feb 25, 2025

Feb 25, 2025

IBD-Focused Spyre Therapeutics Sets Investor Conference Schedule for MarchWhat to Expect - Stock Titan

Feb 25, 2025

Feb 21, 2025

Spyre Therapeutics (NASDAQ:SYRE) Upgraded at The Goldman Sachs Group - Defense World

Feb 21, 2025

Feb 20, 2025

Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Feb 20, 2025

Feb 19, 2025

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Rating of "Buy" by Analysts - MarketBeat

Feb 19, 2025

Feb 19, 2025

Can This Novel Dual-Action IBD Treatment Transform Patient Care? New Data Reveals Promising Results - StockTitan

Feb 19, 2025

Feb 17, 2025

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of “Buy” by Analysts - Defense World

Feb 17, 2025

Feb 15, 2025

1,955 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Acquired by Mirae Asset Global Investments Co. Ltd. - Defense World

Feb 15, 2025

Feb 12, 2025

InvestingPro Fair Value analysis proves accurate on Spyre Therapeutics call - MSN

Feb 12, 2025

Feb 10, 2025

Can Spyre Therapeutics (SYRE) Climb 158.85% to Reach the Level Wall Street Analysts Expect? - MSN

Feb 10, 2025

Feb 10, 2025

InvestingPro Fair Value analysis proves accurate on Spyre Therapeutics call By Investing.com - Investing.com

Feb 10, 2025

Feb 07, 2025

Spyre (SYRE) Unveils Strategic Talent Retention Plan: 35K Options with 10-Year Window - StockTitan

Feb 07, 2025

Feb 06, 2025

China Universal Asset Management Co. Ltd. Makes New Investment in Spyre Therapeutics, Inc. (NASDAQ:SYRE) - MarketBeat

Feb 06, 2025